GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Short Interest


NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
73 GF Score
Price ₹2,354.80
GF Value ₹2,613.51
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NSE:GLAXO vs LLY, JNJ, ABBV: Short Interest Comparison

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Short Interest falls into.


NSE:GLAXO
73GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,354.80 is trading 9.9% below its estimated GF Value™ of ₹2,613.51. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:GLAXO:

  • Short Interest:
  • GF Value™: ₹2,613.51 vs. price of ₹2,354.80 (9.9% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score

Get the complete analysis for NSE:GLAXO

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,354.80
Price
₹2,613.51
GF Value